Nkarta Announces Management Modifications Nasdaq:NKTX

Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Enterprise OfficerAlicia J. Hager,…

Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Enterprise Officer
Alicia J. Hager, J.D., Ph.D. to Sign up for as Main Authorized Officer

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (Globe NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a medical-phase biopharmaceutical company producing engineered pure killer (NK) cell therapies to deal with most cancers, nowadays announced that Nadir Mahmood, Ph.D., Chief Company Officer of Nkarta, is assuming the expanded job of Main Monetary and Enterprise Officer successful instantly. He replaces Matthew Plunkett, Ph.D. who has stepped down as Chief Economic Officer to go after other opportunities. In addition, Alicia J. Hager, J.D., Ph.D. is expected to be part of Nkarta as Main Lawful Officer later on this month.

“We are delighted to welcome Nadir to his recently expanded role at Nkarta,” stated Paul J. Hastings, Main Executive Officer of Nkarta. “Since signing up for the organization in 2018, Nadir has played a direct function in shaping Nkarta’s system and functions, delivered fantastic cross-practical management and shown a deep being familiar with of the quite a few facets of our business enterprise. These achievements, in addition to his expertise in corporate growth and fairness exploration, make him specifically well suited for Nkarta at this stage in our growth. He will be supported by a seasoned finance corporation as we glance ahead to his continued contributions.”

Mahmood said, “I glance ahead to working with our traders, collaborators and the Nkarta crew as we keep on the essential pursuit of advancing the following possible wave of transformative cell therapy that can convey new hope to cancer clients. Building on the solid foundation Matt served to make, we keep on being targeted on growing system innovation, advancing our production abilities, and planning for clinical trials of our potentially disruptive co-lead NK cell therapy candidates.”

Hastings continued, “We would like to thank Matt for his numerous important contributions to Nkarta. His unique talent set of superior scientific schooling and economical marketplace encounter aided us quickly construct our money basis and just take Nkarta to wherever we are currently. I know I communicate for all people at the company when I say we wish Matt nicely as he embarks on the next leg of his productive profession.”

Plunkett additional, “I respect the chance from Paul and the Board to contribute to Nkarta’s funding and functions around the last two decades, and I am delighted to go away the business with a solid monetary basis for foreseeable future achievements.”

“We’re also delighted to welcome Alicia to Nkarta as we broaden the knowledge and capabilities of our excellent management crew,” Hastings additional. “As an skilled main counsel and biopharma government, she will offer crucial legal experience and leadership to assistance our purpose of accelerating the development of groundbreaking therapies.”

About Nadir Mahmood, Ph.D.
Prior to becoming a member of Nkarta in 2018, Dr. Mahmood headed corporate advancement at Next Genome in which he was accountable for developing method and partnerships across the company’s portfolio of programs. Previously in his vocation, he was staff scientist at Kythera Biopharmaceuticals (obtained by Allergan), overseeing preclinical research for the company’s direct molecule, Kybella®. Dr. Mahmood has also worked in fairness study at Goldman Sachs and consulted for early stage firms in the daily life sciences and cleanse strength sectors. He gained a B.S. in Biochemistry from the College of Texas at Austin and a Ph.D. in Cell Regulation from the University of Texas Southwestern Health care Center, and accomplished postdoctoral exploration at the Scripps Analysis Institute in La Jolla, CA.

About Alicia J. Hager, J.D., Ph.D.
Dr. Hager brings to Nkarta a deep scientific background and just about 20 many years of wide legal working experience in the existence sciences. She previously served as Senior Vice President and General Counsel of OncoMed Pharmaceuticals, the place she held several roles of increasing duty and management in excess of the many years. Prior to signing up for OncoMed, Dr. Hager was an legal professional at the law agency of Morrison & Foerster LLP, the place she served as mental home counsel for biotech and pharmaceutical shoppers. Earlier in her vocation, Dr. Hager was a patent agent at the law business of Heller Ehrman White & McAuliffe LLP. Dr. Hager acquired an A.B. in Chemistry from Occidental College or university, an A.M. and Ph.D. in Chemistry from Harvard College and a J.D. from Stanford Law Faculty.

About Nkarta
Nkarta is a medical-stage biotechnology business advancing the growth of allogeneic organic killer (NK) mobile therapies for cancer. By combining its mobile growth and cryopreservation platform with proprietary cell engineering technologies, Nkarta is setting up a pipeline of cell remedy candidates generated by successful production procedures, and engineered to increase tumor focusing on and improve persistence for sustained exercise in the system. For far more information and facts, make sure you check out the company’s internet site at www.nkartatx.com.

Cautionary Be aware on Ahead-Wanting Statements
Statements contained in this push launch regarding issues that are not historical specifics are “forward-searching statements” in just the which means of the Private Securities Litigation Reform Act of 1995, as amended. Terms these types of as “anticipates,” “thinks,” “expects,” “intends,” “plans,” “potential,” “jobs,” “would” and “long run” or related expressions are supposed to detect forward-hunting statements. Illustrations of these ahead-looking statements include statements about: Nkarta’s anticipations regarding its growth and economic situation, the development of its system innovation and production abilities, and the know-how of its executives. For the reason that this kind of statements are subject matter to threats and uncertainties, precise outcomes may possibly vary materially from these expressed or implied by these types of forward-wanting statements. These pitfalls and uncertainties are explained a lot more absolutely in Nkarta’s filings with the Securities and Exchange Commission (“SEC”), such as the “Risk Factors” part of the Company’s Quarterly Report on Variety 10-Q for the quarterly interval finished June 30, 2020, submitted with the SEC on August 20, 2020, and our other paperwork subsequently filed with or furnished to the SEC. All ahead-seeking statements contained in this push release discuss only as of the date on which they have been produced. Except to the extent demanded by legislation, Nkarta undertakes no obligation to update such statements to reflect situations that take place or circumstances that exist after the day on which they had been produced.

Nkarta Media/Trader Get hold of:
Greg Mann
Nkarta, Inc.
[email protected]